Covid-19 costs Coloplast USD 33m in extended court cases

Medtech company Coloplast has set aside a further USD 33m to pay for compensation in the remaning cases over its vaginal mesh product in the US. The covid-19 crisis has delayed court cases and increased the cost of legal counsel, but the financial director expects this amount to be enough to but the cases behind them.

Financial director Anders Lonning-Skovgaard | Photo: Niels Hougaard/ERH

In Coloplast's Q2 financial report released on Thursday there was a special column for the expensive cloud that is still hanging over the medtech company in the US.

This involves the court cases over the vaginal mesh developed by the company to treat uterine prolapse and urinary incontinence that are still haunting the company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs